Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
Abstract
A better mechanistic understanding of the survival benefits and identification of biomarkers of response would greatly enhance the optimal utilization of antiangiogenic agents such as bevacizumab in combination with chemotherapy in the treatment of cancer. This study indicates that the benefits of bevacizumab with chemotherapy in non–small cell lung cancer (NSCLC) patients may depend on tumor vascular function during treatment. These correlative studies also provide new insights into the selection of NSCLC patients most likely to benefit from the addition of bevacizumab treatment to chemotherapy. The imaging and circulating biomarker candidates should be further evaluated in larger studies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 20, 2015
- Source ID
- 10.1073/pnas.1424024112
Entities
People
- Alice T. Shaw
- Dan G Duda
- Dushyant V. Sahani
- Jeffrey A. Engelman
- Jennifer S. Temel
- Joel W. Neal
- Lecia V. Sequist
- Leena Gandhi
- Marek Ancukiewicz
- Nathan A Pennell
- Panos Fidias
- Rakesh Jain
- Rebecca S. Heist
- Thomas J. Lynch
Organizations
- Cleveland Clinic
- Dana–Farber Cancer Institute
- Harvard Medical School
- National Cancer Institute
- Stanford University
- United States Department of Defense
- University of Arizona
- Yale Cancer Center